170 related articles for article (PubMed ID: 9496523)
1. Prognostic value of CA 19-9 serum course in pancreatic cancer.
Safi F; Schlosser W; Falkenreck S; Beger HG
Hepatogastroenterology; 1998; 45(19):253-9. PubMed ID: 9496523
[TBL] [Abstract][Full Text] [Related]
2. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
Safi F; Roscher R; Beger HG
Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
[TBL] [Abstract][Full Text] [Related]
4. CA 19-9 serum course and prognosis of pancreatic cancer.
Safi F; Schlosser W; Falkenreck S; Beger HG
Int J Pancreatol; 1996 Dec; 20(3):155-61. PubMed ID: 9013275
[TBL] [Abstract][Full Text] [Related]
5. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
6. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms.
Safi F; Schlosser W; Kolb G; Beger HG
J Gastrointest Surg; 1997; 1(2):106-12. PubMed ID: 9834336
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.
Lundin J; Roberts PJ; Kuusela P; Haglund C
Anticancer Res; 1995; 15(5B):2181-6. PubMed ID: 8572621
[TBL] [Abstract][Full Text] [Related]
10. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
[TBL] [Abstract][Full Text] [Related]
11. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
[TBL] [Abstract][Full Text] [Related]
12. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
14. Serum CA19-9 determination in the management of pancreatic cancer.
van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J
Hepatogastroenterology; 1996; 43(9):710-3. PubMed ID: 8799418
[TBL] [Abstract][Full Text] [Related]
15. Tumor markers in patients with pancreatic carcinoma.
Gattani AM; Mandeli J; Bruckner HW
Cancer; 1996 Jul; 78(1):57-62. PubMed ID: 8646727
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative predictors of short-term survival after pancreatic cancer resection.
Takeuchi M; Kondo S; Sugiura H; Katoh H
Hepatogastroenterology; 1998; 45(24):2399-403. PubMed ID: 9951931
[TBL] [Abstract][Full Text] [Related]
18. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
20. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
